311 related articles for article (PubMed ID: 22395984)
1. Surgical complications in gastric cancer patients preoperatively treated with chemotherapy: their risk factors and clinical relevance.
An JY; Kim KM; Kim YM; Cheong JH; Hyung WJ; Noh SH
Ann Surg Oncol; 2012 Aug; 19(8):2452-8. PubMed ID: 22395984
[TBL] [Abstract][Full Text] [Related]
2. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
Moon YW; Jeung HC; Rha SY; Yoo NC; Roh JK; Noh SH; Kim BS; Chung HC
Ann Surg Oncol; 2007 Oct; 14(10):2730-7. PubMed ID: 17632757
[TBL] [Abstract][Full Text] [Related]
3. P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy.
Díez M; Medrano MJ; Gutierrez A; López A; Mugüerza JM; Hernández P; Lozano O; Noguerales F; Ruíz A; Granell J
Anticancer Res; 2000; 20(5C):3929-33. PubMed ID: 11268479
[TBL] [Abstract][Full Text] [Related]
4. Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer.
Fujitani K; Mano M; Hirao M; Kodama Y; Tsujinaka T
Ann Surg Oncol; 2012 Jun; 19(6):1936-43. PubMed ID: 22187120
[TBL] [Abstract][Full Text] [Related]
5. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients.
Romano F; Cesana G; Berselli M; Gaia Piacentini M; Caprotti R; Bovo G; Uggeri F
J Surg Oncol; 2004 Dec; 88(4):240-7. PubMed ID: 15565596
[TBL] [Abstract][Full Text] [Related]
6. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer?
Mansour JC; Tang L; Shah M; Bentrem D; Klimstra DS; Gonen M; Kelsen DP; Brennan MF; Coit DG
Ann Surg Oncol; 2007 Dec; 14(12):3412-8. PubMed ID: 17909917
[TBL] [Abstract][Full Text] [Related]
7. [Multivariate prognostic analysis in gastric carcinoma patients after radical operation].
Zhan YQ; Sun XW; Li W; Chen YB; Xu L; Guan YX; Li YF; Xu DZ
Ai Zheng; 2005 May; 24(5):596-9. PubMed ID: 15890105
[TBL] [Abstract][Full Text] [Related]
8. Current concepts in gastric cancer surgery.
Schumacher IK; Hunsicker A; Youssef PS; Lorenz D
Saudi Med J; 2002 Jan; 23(1):62-8. PubMed ID: 11938366
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single institute.
Cho BC; Jeung HC; Choi HJ; Rha SY; Hyung WJ; Cheong JH; Noh SH; Chung HC
J Surg Oncol; 2007 May; 95(6):461-8. PubMed ID: 17192913
[TBL] [Abstract][Full Text] [Related]
10. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases.
Becker K; Langer R; Reim D; Novotny A; Meyer zum Buschenfelde C; Engel J; Friess H; Hofler H
Ann Surg; 2011 May; 253(5):934-9. PubMed ID: 21490451
[TBL] [Abstract][Full Text] [Related]
11. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients.
Romano F; Piacentini MG; Franciosi C; Caprotti R; De Fina S; Cesana G; Uggeri F; Conti M; Uggeri F
Hepatogastroenterology; 2004; 51(60):1872-6. PubMed ID: 15532847
[TBL] [Abstract][Full Text] [Related]
12. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients.
Lorenzen S; Blank S; Lordick F; Siewert JR; Ott K
Ann Surg Oncol; 2012 Jul; 19(7):2119-27. PubMed ID: 22395980
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer.
Barone C; Cassano A; Pozzo C; D'Ugo D; Schinzari G; Persiani R; Basso M; Brunetti IM; Longo R; Picciocchi A
Oncology; 2004; 67(1):48-53. PubMed ID: 15459495
[TBL] [Abstract][Full Text] [Related]
14. Palliative gastrectomy and other factors affecting overall survival in stage IV gastric adenocarcinoma patients receiving chemotherapy: a retrospective analysis.
Sougioultzis S; Syrios J; Xynos ID; Bovaretos N; Kosmas C; Sarantonis J; Dokou A; Tzivras D; Zografos G; Felekouras E; Papalambros E; Tsavaris N
Eur J Surg Oncol; 2011 Apr; 37(4):312-8. PubMed ID: 21300519
[TBL] [Abstract][Full Text] [Related]
15. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer.
Reim D; Gertler R; Novotny A; Becker K; zum Büschenfelde CM; Ebert M; Dobritz M; Langer R; Hoefler H; Friess H; Schumacher C
Ann Surg Oncol; 2012 Jul; 19(7):2108-18. PubMed ID: 22130620
[TBL] [Abstract][Full Text] [Related]
16. Results of immunochemo-surgery for gastric carcinoma.
Kim JP; Yu HJ; Lee JH
Hepatogastroenterology; 2001; 48(41):1227-30. PubMed ID: 11677936
[TBL] [Abstract][Full Text] [Related]
17. 7-Year survival results of perioperative chemotherapy with epidoxorubicin, etoposide, and cisplatin (EEP) in locally advanced resectable gastric cancer: up-to-date analysis of a phase-II study.
Persiani R; Rausei S; Pozzo C; Biondi A; Barone C; Cananzi FC; Schinzari G; D'Ugo D
Ann Surg Oncol; 2008 Aug; 15(8):2146-52. PubMed ID: 18543037
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of complications after curative surgery for gastric cancer.
Kubota T; Hiki N; Sano T; Nomura S; Nunobe S; Kumagai K; Aikou S; Watanabe R; Kosuga T; Yamaguchi T
Ann Surg Oncol; 2014 Mar; 21(3):891-8. PubMed ID: 24254205
[TBL] [Abstract][Full Text] [Related]
19. Intraoperative radiotherapy combined with adjuvant chemoradiotherapy for locally advanced gastric adenocarcinoma.
Fu S; Lu JJ; Zhang Q; Yang Z; Peng L; Xiong F
Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1488-94. PubMed ID: 18538489
[TBL] [Abstract][Full Text] [Related]
20. Gastric carcinoma: curative resection and adjuvant chemotherapy.
Carrillo Hernández JF; Ernesto de Obaldía Castillo G; Ramírez Ortega C; Frías Mendivil M; Pardo M
Arch Med Res; 1994; 25(1):29-35. PubMed ID: 8019111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
